|
WO2020255837A1
|
|
Timed-elution masking particles and oral pharmaceutical composition containing same
|
|
WO2020090967A1
|
|
Fibrosis-inducing gene expression inhibitor and use thereof
|
|
WO2020080380A1
|
|
Coated solid preparation
|
|
WO2020045456A1
|
|
Drug-containing particle
|
|
WO2020040233A1
|
|
Specifically-shaped crystal of compound and method for producing same
|
|
US2021059948A1
|
|
Cyclic orally disintegrating tablet
|
|
WO2018190294A1
|
|
Medicinal composition comprising escitalopram
|
|
EP3446684A1
|
|
Orally disintegrating tablet
|
|
US2019125666A1
|
|
Orally disintegrating tablet
|
|
WO2016051609A1
|
|
Drug comprising lanthanum carbonate hydrate having adjusted particle size
|
|
WO2014050874A1
|
|
Novel crystalline form of rosuvastatin calcium and production method therefor
|
|
JPH11349479A
|
|
Stable enalapril maleate tablet
|
|
JPH11335295A
|
|
Stable aqueous solution preparation of calcium-controlling polypeptide hormone for parenteral administration
|
